Skip to content
Search AI Powered

Latest Stories

Levomepromazine 25mg/1ml solution for injection faces supply disruption

Levomepromazine 25mg/1ml solution for injection will remain unavailable until the week commencing March 7,2022, Department of Health and Social Care (DHSC) said in an update.

While alternative medicines for use in palliative care remain available in ample supply to support an uplift in demand, the date supply resumption of Levomepromazine is yet to be confirmed.


The DHSC has sent a copy of this medicine supply notification to all pharmacy NHS email addresses.

It further informed primary care providers that prescription validation has been temporarily implemented at wholesaler level.

To ensure continuity of supply to patients, the department has advised community pharmacists to work with their local hospitals and request mutual aid if wholesaler supplies are exhausted.

In case pharmacists are not able to secure supplies via mutual aid, they should work with specialist palliative care teams to use alternative medication, the DHSC stated.

More For You

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Prakash Patel was speaking at a panel discussion at the Sigma Conference

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Pharmacists need to be a part of integrated care boards (ICB) to stop GPs from monopolising services based on their needs rather than the needs of the patient, according to Prakash Patel, Community Pharmacy Engaland (CPE) representative for North London.

“The evolution of the NHS should mean there can be no decision of pharmacy without pharmacist,” Patel told delegates at the Sigma Pharmacy Conference in Baku, Azerbaijan on Tuesday.

Keep ReadingShow less
David Webb
David Webb, NHS England's Chief Pharmaceutical Officer
David Webb, NHS England's Chief Pharmaceutical Officer

Sigma Conference: "Community pharmacy ready to make a profound contribution to 10 Year Health Plan," says David Webb

A national community pharmacy prescribing service remains a long-term goal of the government, according to NHS chief pharmaceutical officer, David Webb.

The Labour Party in its election manifesto last year said it would “create a Community Pharmacist Prescribing Service, granting more pharmacists independent prescribing rights”.

Keep ReadingShow less
Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less